.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Teva
Deloitte
Farmers Insurance
Colorcon
Healthtrust
Daiichi Sankyo
US Army
Express Scripts
Argus Health

Generated: November 22, 2017

DrugPatentWatch Database Preview

RISPERDAL Drug Profile

« Back to Dashboard

What is the patent landscape for Risperdal, and what generic Risperdal alternatives are available?

Risperdal is a drug marketed by Janssen Pharms and is included in four NDAs. There are eight patents protecting this drug and two Paragraph IV challenges.

This drug has thirty-six patent family members in twenty-seven countries and one supplementary protection certificate in one country.

The generic ingredient in RISPERDAL is risperidone. There are thirty drug master file entries for this compound. Fifty-nine suppliers are listed for this compound. Additional details are available on the risperidone profile page.

Pharmacology for RISPERDAL

Medical Subject Heading (MeSH) Categories for RISPERDAL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Janssen Pharms
RISPERDAL CONSTA
risperidone
INJECTABLE;INTRAMUSCULAR021346-002Oct 29, 2003RXYesNo► Subscribe► SubscribeY► Subscribe
Janssen Pharms
RISPERDAL CONSTA
risperidone
INJECTABLE;INTRAMUSCULAR021346-002Oct 29, 2003RXYesNo► Subscribe► SubscribeY► Subscribe
Janssen Pharms
RISPERDAL CONSTA
risperidone
INJECTABLE;INTRAMUSCULAR021346-002Oct 29, 2003RXYesNo► Subscribe► SubscribeY► Subscribe
Janssen Pharms
RISPERDAL CONSTA
risperidone
INJECTABLE;INTRAMUSCULAR021346-002Oct 29, 2003RXYesNo► Subscribe► SubscribeY► Subscribe
Janssen Pharms
RISPERDAL
risperidone
TABLET, ORALLY DISINTEGRATING;ORAL021444-001Apr 2, 2003ABRXYesNo► Subscribe► SubscribeY► Subscribe
Janssen Pharms
RISPERDAL CONSTA
risperidone
INJECTABLE;INTRAMUSCULAR021346-004Apr 12, 2007RXYesNo► Subscribe► SubscribeY► Subscribe
Janssen Pharms
RISPERDAL CONSTA
risperidone
INJECTABLE;INTRAMUSCULAR021346-001Oct 29, 2003RXYesYes► Subscribe► SubscribeY► Subscribe
Janssen Pharms
RISPERDAL CONSTA
risperidone
INJECTABLE;INTRAMUSCULAR021346-003Oct 29, 2003RXYesNo► Subscribe► SubscribeY► Subscribe
Janssen Pharms
RISPERDAL
risperidone
TABLET;ORAL020272-007Jan 27, 1999ABRXYesNo► Subscribe► Subscribe► Subscribe
Janssen Pharms
RISPERDAL CONSTA
risperidone
INJECTABLE;INTRAMUSCULAR021346-003Oct 29, 2003RXYesNo► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: RISPERDAL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Janssen Pharms
RISPERDAL
risperidone
TABLET;ORAL020272-001Dec 29, 1993► Subscribe► Subscribe
Janssen Pharms
RISPERDAL
risperidone
TABLET;ORAL020272-007Jan 27, 1999► Subscribe► Subscribe
Janssen Pharms
RISPERDAL
risperidone
TABLET;ORAL020272-008May 10, 1999► Subscribe► Subscribe
Janssen Pharms
RISPERDAL
risperidone
TABLET, ORALLY DISINTEGRATING;ORAL021444-001Apr 2, 2003► Subscribe► Subscribe
Janssen Pharms
RISPERDAL
risperidone
SOLUTION;ORAL020588-001Jun 10, 1996► Subscribe► Subscribe
Janssen Pharms
RISPERDAL
risperidone
TABLET;ORAL020272-003Dec 29, 1993► Subscribe► Subscribe
Janssen Pharms
RISPERDAL
risperidone
TABLET, ORALLY DISINTEGRATING;ORAL021444-002Apr 2, 2003► Subscribe► Subscribe
Janssen Pharms
RISPERDAL
risperidone
TABLET, ORALLY DISINTEGRATING;ORAL021444-003Apr 2, 2003► Subscribe► Subscribe
Janssen Pharms
RISPERDAL
risperidone
TABLET;ORAL020272-003Dec 29, 1993► Subscribe► Subscribe
Janssen Pharms
RISPERDAL
risperidone
TABLET;ORAL020272-004Dec 29, 1993► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for RISPERDAL

Drugname Dosage Strength RLD Submissiondate
risperidoneOrally Disintegrating Tablets0.25 mgRisperdal4/11/2005
risperidoneOrally Disintegrating Tablets3 mg and 4 mgRisperdal3/23/2005

International Patent Family for Tradename: RISPERDAL

Country Document Number Estimated Expiration
South Africa9705277► Subscribe
Israel127603► Subscribe
South Korea20000015849► Subscribe
Japan4371435► Subscribe
New Zealand332832► Subscribe
Slovenia910345► Subscribe
Norway985876► Subscribe
Australia3175797► Subscribe
Brazil9709829► Subscribe
Cyprus2288► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: RISPERDAL

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0008Belgium► SubscribePRODUCT NAME: RISPERIDONE; NAT REG.: 2 S 414 F 3 19940527; FIRST REG.: GB 0242/0186 19921208
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
McKesson
AstraZeneca
Baxter
Fuji
Farmers Insurance
Harvard Business School
McKinsey
UBS
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot